Bicocca Open Archive

Logo unimib boa
ZAMBELLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.282
NA - Nord America 4.914
EU - Europa 2.401
SA - Sud America 2.205
AF - Africa 245
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 24.058
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 6.407
US - Stati Uniti d'America 4.595
SG - Singapore 3.132
CN - Cina 2.051
BR - Brasile 1.669
HK - Hong Kong 1.183
IT - Italia 522
RU - Federazione Russa 477
KR - Corea 303
DE - Germania 300
FR - Francia 292
BD - Bangladesh 236
IN - India 201
AR - Argentina 178
CA - Canada 157
ID - Indonesia 137
FI - Finlandia 129
IQ - Iraq 121
SE - Svezia 120
GB - Regno Unito 112
EC - Ecuador 105
MX - Messico 102
IE - Irlanda 84
UA - Ucraina 78
ZA - Sudafrica 78
PK - Pakistan 77
CO - Colombia 73
TR - Turchia 73
AT - Austria 64
PY - Paraguay 60
NL - Olanda 59
SA - Arabia Saudita 48
PH - Filippine 47
UZ - Uzbekistan 44
JP - Giappone 41
CL - Cile 40
VE - Venezuela 40
MA - Marocco 37
ES - Italia 36
TN - Tunisia 30
MY - Malesia 24
JO - Giordania 23
RO - Romania 23
PE - Perù 22
PL - Polonia 22
KE - Kenya 21
EG - Egitto 18
DZ - Algeria 16
UY - Uruguay 14
AE - Emirati Arabi Uniti 13
NP - Nepal 13
DK - Danimarca 12
ET - Etiopia 12
AZ - Azerbaigian 11
CH - Svizzera 11
CR - Costa Rica 11
JM - Giamaica 11
OM - Oman 11
PS - Palestinian Territory 10
TH - Thailandia 9
AL - Albania 7
IL - Israele 7
LB - Libano 7
TT - Trinidad e Tobago 7
AU - Australia 6
CZ - Repubblica Ceca 6
KZ - Kazakistan 6
LT - Lituania 6
PT - Portogallo 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
GE - Georgia 5
KW - Kuwait 5
NI - Nicaragua 5
BB - Barbados 4
BE - Belgio 4
GT - Guatemala 4
HU - Ungheria 4
IR - Iran 4
LK - Sri Lanka 4
NG - Nigeria 4
PA - Panama 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TG - Togo 4
TW - Taiwan 4
AM - Armenia 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
EU - Europa 3
GA - Gabon 3
HN - Honduras 3
HR - Croazia 3
KG - Kirghizistan 3
LV - Lettonia 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
BT - Bhutan 2
Totale 24.016
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 2.021
Hanoi 1.662
Singapore 1.338
Hong Kong 1.168
San Jose 712
Hefei 700
Ashburn 508
Seoul 298
Ann Arbor 259
Chicago 236
Los Angeles 200
Da Nang 197
Lauterbourg 188
Haiphong 173
Beijing 172
Council Bluffs 161
The Dalles 158
Quận Bình Thạnh 140
Dallas 135
New York 134
Ha Long 128
Fairfield 126
Frankfurt am Main 126
São Paulo 123
Biên Hòa 121
Buffalo 111
Vũng Tàu 108
Woodbridge 107
Ninh Bình 104
Quận Một 95
Chandler 94
Toronto 94
Thái Nguyên 91
Milan 90
Hải Dương 89
Bắc Ninh 82
Dublin 82
Jakarta 79
Helsinki 75
Houston 72
Can Tho 71
Seattle 71
Nuremberg 68
Moscow 67
Santa Clara 66
Rio de Janeiro 61
Wilmington 61
Phủ Lý 57
Quận Phú Nhuận 53
Baghdad 52
Vinh 49
Bắc Giang 45
Lappeenranta 45
Shanghai 43
Jacksonville 40
Mexico City 40
Quito 39
Dearborn 38
Tashkent 38
Thái Bình 38
Quận Tân Phú 37
Cambridge 36
Guangzhou 36
Quận Sáu 35
Paris 34
Lang Son 32
Curitiba 31
Lấp Vò 31
Vienna 31
Vĩnh Tường 31
Princeton 30
Brasília 29
Dhaka 29
Asunción 28
Thu Dau Mot 28
Tokyo 28
Guayaquil 27
Hòa Bình 27
Kent 27
Munich 27
Nam Định 26
Điện Bàn 26
Quảng Ninh 24
Quận Năm 24
Belo Horizonte 23
Cà Mau 23
Johannesburg 23
Porto Alegre 23
Nanjing 22
Quận Bốn 22
Quận Hai 22
Riyadh 22
Rome 22
Bình Dương 21
Campinas 21
Dong Ket 21
Huế 21
Istanbul 21
Lahore 21
Phan Thiết 21
Totale 14.662
Salva come PNG Salva come JPEG
Nome #
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 790
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 566
Short commentaries on data published by Petit et al. on locoregional risk after lipofilling in breast cancer patients 544
Analysis of SEMA6B gene expression in breast cancer: Identification of a new isoform 508
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 435
Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study 372
No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer 371
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression 339
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 336
Targeting triple negative breast cancer: Is p53 the answer? 332
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy 316
Management and Survival of Pleural Mesothelioma: A Record Linkage Study 297
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival 291
Retinoids and breast cancer: from basic studies to the clinic and back again 281
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 281
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 258
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 252
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. 238
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study 237
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study 223
Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway 218
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 208
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 207
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 198
Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists 189
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 184
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors 181
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems 177
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 175
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 174
ACUTE UPPER GASTROINTESTINAL BLEEDING (AUGB) IN ITALY: AN INTERIM ANALYSIS OF THE ORGANIZATIONAL ASPECTS CARING AN EVOLVING DISEASE 174
A network-based data integration approach to support drug repurposing and multi-Target therapies in triple negative breast cancer 173
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 172
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 171
Transfusion Strategy and Death Risk in Patients with Acute Non-Variceal Upper Gastro Intestinal Bleeding (NV-UGIB) in Italy: A Prospective Multicenter Observational Study 164
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates 161
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial) 158
BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork 155
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 155
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 154
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses 153
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer 153
Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations 152
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry 151
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy 149
Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer 145
ONCO-i2b2: improve patients selection through CBR techniques with heterogeneous distance functions 145
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 145
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 145
Tyrosine kinase inhibitors and QTc intervals: A class effect 144
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 137
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 136
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 135
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 133
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 133
Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care 132
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al 131
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 129
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 126
The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort 124
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 123
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 122
The central role of pathology labs in breast cancer precision oncology: a call for action 121
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 121
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 121
i2b2 to optimize patients enrollment 120
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients 120
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 117
Correction to: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors (Journal of Endocrinological Investigation, (2023), 47, 2, (433-442), 10.1007/s40618-023-02174-5) 117
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 117
Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study 114
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 114
Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) 113
Clinical Review on the Management of Breast Cancer Visceral Crisis 113
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 112
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 111
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 111
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 109
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 107
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis 107
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis 105
The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy 104
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium 103
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 102
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 102
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 102
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy 102
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 101
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review 101
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 100
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 100
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 99
Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer 99
Evolving phenotypes of non-hospitalized patients that indicate long COVID 97
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 97
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 97
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer - Immun-HER trial (GOIRC-01-2016) 96
International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality 96
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 95
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 94
Totale 17.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 0 0 0 0 0 21 64
2021/2022201 17 23 36 12 4 13 5 8 8 21 25 29
2022/2023357 35 123 36 22 22 49 0 22 22 1 15 10
2023/2024213 5 6 11 8 32 50 42 8 19 0 7 25
2024/20254.752 31 74 15 28 60 646 313 116 318 644 455 2.052
2025/202618.156 4.958 3.266 1.345 2.022 831 530 1.557 763 1.050 1.195 639 0
Totale 24.726